Laventair Ellipta (previously Laventair)

RSS

umeclidinium bromide / vilanterol

Authorised
This medicine is authorised for use in the European Union.

Overview

Laventair Ellipta is a medicine used to relieve the symptoms of chronic obstructive pulmonary disease (COPD) in adults. COPD is a long-term disease in which the airways and air sacs inside the lungs become damaged or blocked, leading to difficulty breathing. Laventair Ellipta is used for maintenance (regular) treatment.

Laventair Ellipta contains the active substances umeclidinium bromide and vilanterol.

This EPAR was last updated on 17/10/2019

Authorisation details

Product details
Name
Laventair Ellipta (previously Laventair)
Agency product number
EMEA/H/C/003754
Active substance
  • umeclidinium bromide
  • vilanterol
International non-proprietary name (INN) or common name
umeclidinium bromide / vilanterol
Therapeutic area (MeSH)
Pulmonary Disease, Chronic Obstructive
Anatomical therapeutic chemical (ATC) code
R03AL03
Additional monitoringAdditional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Publication details
Marketing-authorisation holder
GlaxoSmithKline (Ireland) Limited
Revision
12
Date of issue of marketing authorisation valid throughout the European Union
08/05/2014
Contact address

12 Riverwalk
Citywest Business Campus
Dublin 24
Ireland

Product information

19/09/2019 Laventair Ellipta (previously Laventair) - EMEA/H/C/003754 - WS/1501

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Drugs for obstructive airway diseases

Therapeutic indication

Laventair Ellipta is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).

Assessment history

How useful was this page?

Add your rating